Gastric CancerNCT06027242
Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
A study testing oral glutamine and Maltodextrin in people with Gastric Cancer and Immunonutrition, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Gastric Cancer, Immunonutrition, Gastrostomy
- What is being tested?
- oral glutamine and Maltodextrin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteTaiwan
- Study dates
- 21 Feb 2023to 30 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- adult gastric cancer receiving gastrectomy
Who cannot join
- Hepatic insufficiency
- Renal insufficiency
- can not tolerate oral or enteral feeding 7 days after gastrectomy
- can not receive computed tomograph
- can not waer the wearable devices
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ming-Tsan Lin, MD contact
Taiwan1 site, 1 recruiting
- Recruiting
National Taiwan University Hospital
Taipei, 100
Jin-Ming Wu, MD, 886-223123456, wujm0531@gmail.com
About this study
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
Read the detailed description
This will be a double-blind, randomized, and placebo-controlled study. At least 80 evaluable patients who are scheduled for gastrectomy for gastric adenocarcinoma cancer will be randomly assigned to the control or treatment group. Each group will have at least 40 patients. The CT scan will be evaluated before surgery and on postoperative day (POD) 90. Moreover, the patient will wear the smart watch to record daily walking steps. Laboratory data will be check before gastrectomy and on POD 90.
- Conditions
- Gastric Cancer, Immunonutrition, Gastrostomy
- Being tested
- oral glutamine, Maltodextrin
- Keywords
- Gastric cancer, Gastrectomy, sarcopenia
- Medical subject headings
- Stomach Neoplasms, Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
oral glutamineDietary supplement
10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
MaltodextrinDietary supplement
Maltodextrin
| Study group | Role | What they receive |
|---|---|---|
| Without oral glutamine supplementation | Placebo comparator | 15 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding Receives: Dietary Supplement: Maltodextrin |
| With oral glutamine supplementation | Active comparator | 10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding Receives: Dietary Supplement: oral glutamine; Dietary Supplement: Maltodextrin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of area of psoas muscle
area od psoas muscle on the CT scan
Measured: 84 days after gastrectomy
Secondary outcomes (6)
Walking steps
the average daily walking steps recorded by the wearable devices
Measured: 28,56, and 84 days after gastrectomy
body weight
body weight
Measured: 84 days after gastrectomy
Change of serum albumin value
Measured: 84 days after gastrectomy
Change in white blood cells counts
Measured: 84 days after gastrectomy
Change in lymphocyte cells counts
Measured: 84 days after gastrectomy
Change of serum pre-albumin value
Measured: 84 days after gastrectomy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Sep 2023
- Study start21 Feb 2023
- Primary completion30 Aug 2026 (estimated)
- Study completion30 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, National Taiwan University Clinical Trial Center, National Taiwan University Hospital
- Investigators
- Jin-Ming Wu, MD, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06027242
- Sponsor's protocol ID
- 202207099RINA
- Status last verified
- Dec 2025
- First submitted
- 17 Aug 2023
- Last updated
- 23 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
- ClinicalTrials.gov ID
- NCT06027242
- Acronym / sponsor ID
- 202207099RINA
- Conditions
- Gastric Cancer, Immunonutrition, Gastrostomy
- Keywords
- Gastric cancer, Gastrectomy, sarcopenia
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 21 Feb 2023 (actual)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 30 Aug 2026 (estimated)
- First posted
- 7 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
Detailed description
This will be a double-blind, randomized, and placebo-controlled study. At least 80 evaluable patients who are scheduled for gastrectomy for gastric adenocarcinoma cancer will be randomly assigned to the control or treatment group. Each group will have at least 40 patients. The CT scan will be evaluated before surgery and on postoperative day (POD) 90. Moreover, the patient will wear the smart watch to record daily walking steps. Laboratory data will be check before gastrectomy and on POD 90.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Without oral glutamine supplementation | Placebo comparator | Dietary Supplement: Maltodextrin15 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding |
| With oral glutamine supplementation | Active comparator | Dietary Supplement: oral glutamine, Dietary Supplement: Maltodextrin10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- adult gastric cancer receiving gastrectomy
Key exclusion criteria (5 listed)
- Hepatic insufficiency
- Renal insufficiency
- can not tolerate oral or enteral feeding 7 days after gastrectomy
- can not receive computed tomograph
- can not waer the wearable devices
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| oral glutamine10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding | Dietary supplement | With oral glutamine supplementation |
| MaltodextrinMaltodextrin | Dietary supplement | With oral glutamine supplementation, Without oral glutamine supplementation |
Primary outcome
Change of area of psoas muscle
Time frame: 84 days after gastrectomy
area od psoas muscle on the CT scan
6 secondary outcomes
Walking steps
Time frame: 28,56, and 84 days after gastrectomy
body weight
Time frame: 84 days after gastrectomy
Change of serum albumin value
Time frame: 84 days after gastrectomy
Change in white blood cells counts
Time frame: 84 days after gastrectomy
Change in lymphocyte cells counts
Time frame: 84 days after gastrectomy
Change of serum pre-albumin value
Time frame: 84 days after gastrectomy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Gastric Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 2
Avutometinib and Defactinib in Diffuse Gastric Cancer
Gastric Cancer, Stomach Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ming-Tsan Lin, MD contact
Jin-Ming Wu, MD principal investigator
National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing oral glutamine and Maltodextrin in people with Gastric Cancer and Immunonutrition, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jin-Ming Wu, MD (886+223123456, wujm0531@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of area of psoas muscle (time frame: 84 days after gastrectomy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2025; AzTrials last refreshed its copy on 8 Nov 2026.